1. Mauro E, de Castro T, Zeitlhoefler M, Sung MW, Villanueva A, Mazzaferro V, et al. Hepatocellular carcinoma: epidemiology, diagnosis and treatment. JHEP Rep. 2025;7(12):101571. [
DOI:10.1016/j.jhepr.2025.101571] [
PMID] [
PMCID]
2. Méndez-Sánchez N, Valencia-Rodríguez A, Coronel-Castillo CE, Qi X. Narrative review of hepatocellular carcinoma: from molecular bases to therapeutic approach. Dig Med Res. 2021;4:15. [
DOI:10.21037/dmr-20-116]
3. Ma L, Chen S, Wang H, Chen L. Hepatitis B virus integration and hepatocarcinogenesis. Liver Res. 2025;9(3):189-98. [
DOI:10.1016/j.livres.2025.09.002] [
PMID] [
PMCID]
4. Liang W, Zhao Y, Meng Q, Jiang W, Deng S, Xue J. The role of long non-coding RNA in hepatocellular carcinoma. Aging (Albany NY). 2024;16(4):4052-73. [
DOI:10.18632/aging.205523] [
PMID] [
PMCID]
5. Zhang H, Liao Z, Liu F, Su C, Zhu H, Li Y, et al. Long noncoding RNA HULC promotes hepatocellular carcinoma progression. Aging (Albany NY). 2019;11(20):9111-27. [
DOI:10.18632/aging.102378] [
PMID] [
PMCID]
6. Xin X, Wu M, Meng Q, Wang C, Lu Y, Yang Y, et al. Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a. Mol Cancer. 2018;17(1):94. [
DOI:10.1186/s12943-018-0843-8] [
PMID] [
PMCID]
7. Qiu L, Wang T, Xu X, Wu Y, Tang Q, Chen K. Long non-coding RNAs in hepatitis B virus-related hepatocellular carcinoma: regulation, functions, and underlying mechanisms. Int J Mol Sci. 2017;18(12):2505. [
DOI:10.3390/ijms18122505] [
PMID] [
PMCID]
8. Elzein SM, Brombosz EW, Kodali S. Liver transplantation for cancer-current challenges and emerging solutions. J Clin Med. 2025;14(15):5365. [
DOI:10.3390/jcm14155365] [
PMID] [
PMCID]
9. Yousef EH, El Gayar AM, El-Magd NFA. Insights into sorafenib resistance in hepatocellular carcinoma: mechanisms and therapeutic aspects. Crit Rev Oncol Hematol. 2025;212:104765. [
DOI:10.1016/j.critrevonc.2025.104765] [
PMID]
10. Yoo SY, Badrinath N, Woo HY, Heo J. Oncolytic virus-based immunotherapies for hepatocellular carcinoma. Mediators Inflamm. 2017;2017:5198798. [
DOI:10.1155/2017/5198798] [
PMID] [
PMCID]
11. Li Y, Shen Y, Zhao R, Samudio I, Jia W, Bai X, et al. Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: the key to breaking the log jam? Cancer Med. 2020;9(9):2943-59. [
DOI:10.1002/cam4.2949] [
PMID] [
PMCID]
12. Moon H, Ro SW. MAPK/ERK signaling pathway in hepatocellular carcinoma. Cancers (Basel). 2021;13(12):3026. [
DOI:10.3390/cancers13123026] [
PMID] [
PMCID]
13. Kazemi R, Ataei-Pirkooh A, Aghasadeghi MR, Modaresi MH, Hamidi-Fard M. Human reovirus serotype 3 effectively targets Huh-7 cells. Iran J Virol. 2020;14(2):23-8.
14. Kazemi R, Ataei-Pirkooh A, Aghasadeghi MR, Etemadzadeh MH, Alavian SM, Ghanaati H, et al. The effects of human reoviruses on cancer cells derived from hepatocellular carcinoma biopsies. Clin Lab. 2021;67(3):681-7. [
DOI:10.7754/Clin.Lab.2020.200416] [
PMID]
15. Fu LY, Jia HL, Dong QZ, Wu JC, Zhao Y, Zhou HJ, et al. Suitable reference genes for real-time PCR in human HBV-related hepatocellular carcinoma with different clinical prognoses. BMC Cancer. 2009;9:49. [
DOI:10.1186/1471-2407-9-49] [
PMID] [
PMCID]
16. Gao Q, Wang XY, Fan J, Qiu SJ, Zhou J, Shi YH, et al. Selection of reference genes for real-time PCR in human hepatocellular carcinoma tissues. J Cancer Res Clin Oncol. 2008;134(9):979-86. [
DOI:10.1007/s00432-008-0369-3] [
PMID] [
PMCID]
17. Tyler KL, Sokol RJ, Oberhaus SM, Le M, Karrer FM, Narkewicz MR, et al. Detection of reovirus RNA in hepatobiliary tissues from patients with extrahepatic biliary atresia and choledochal cysts. Hepatology. 1998;27(6):1475-82. [
DOI:10.1002/hep.510270603] [
PMID]
18. Radonić A, Thulke S, Mackay IM, Landt O, Siegert W, Nitsche A. Guideline to reference gene selection for quantitative real-time PCR. Biochem Biophys Res Commun. 2004;313(4):856-62. [
DOI:10.1016/j.bbrc.2003.11.177] [
PMID]
19. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, et al. Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology. 2007;132(1):330-42. [
DOI:10.1053/j.gastro.2006.08.026] [
PMID]
20. Rodríguez Stewart RM, Berry JT, Berger AK, Yoon SB, Hirsch AL, Guberman JA, et al. Enhanced killing of triple-negative breast cancer cells by reassortant reovirus and topoisomerase inhibitors. J Virol. 2019;93(23):e01411-19. [
DOI:10.1128/JVI.01411-19] [
PMID] [
PMCID]
21. Müller L, Berkeley R, Barr T, Ilett E, Errington-Mais F. Past, present and future of oncolytic reovirus. Cancers (Basel). 2020;12(11):3219. [
DOI:10.3390/cancers12113219] [
PMID] [
PMCID]
22. Berry JT, Muñoz LE, Stewart RMR, Selvaraj P, Mainou BA. Doxorubicin conjugation to reovirus improves oncolytic efficacy in triple-negative breast cancer. Mol Ther Oncolytics. 2020;18:556-72. [
DOI:10.1016/j.omto.2020.08.008] [
PMID] [
PMCID]
23. Jiffry J, Thavornwatanayong T, Rao D, Fogel EJ, Saytoo D, Nahata R, et al. Oncolytic reovirus (pelareorep) induces autophagy in KRAS-mutated colorectal cancer. Clin Cancer Res. 2021;27(3):865-76. [
DOI:10.1158/1078-0432.CCR-20-2385] [
PMID] [
PMCID]
24. Pérez-Domínguez F, Quezada-Monrás C, Cárcamo L, Muñoz JP, Carrillo-Beltrán D. Oncolytic viruses as a novel therapeutic approach for colorectal cancer: mechanisms, current advances, and future directions. Cancers (Basel). 2025;17(11):1854. [
DOI:10.3390/cancers17111854] [
PMID] [
PMCID]
25. Rastegarpanah M, Kafi ZZ, Negahdari B. In vivo tracking modalities for oncolytic reovirus: principles, clinical applications, and translational integration. Mol Imaging Biol. 2026;28(3):400-16. [
DOI:10.1007/s11307-026-02092-x] [
PMID]
26. Kitabayashi J, Shirasaki T, Shimakami T, Nishiyama T, Welsch C, Funaki M, et al. Upregulation of the long noncoding RNA HULC by hepatitis C virus and its regulation of viral replication. J Infect Dis. 2022;226(3):407-19. [
DOI:10.1093/infdis/jiaa325] [
PMID] [
PMCID]
27. Sharma G, Tripathi SK, Das S. lncRNA HULC facilitates efficient loading of HCV-core protein onto lipid droplets and subsequent virus-particle release. Cell Microbiol. 2019;21(10):e13086. [
DOI:10.1111/cmi.13086]
28. Liu Y, Feng J, Sun M, Yang G, Yuan H, Wang Y, et al. Long non-coding RNA HULC activates HBV by modulating HBx/STAT3/miR-539/APOBEC3B signaling in HBV-related hepatocellular carcinoma. Cancer Lett. 2019;454:158-70. [
DOI:10.1016/j.canlet.2019.04.008] [
PMID]
29. Meng XY, Luo Y, Anwar MN, Sun Y, Gao Y, Zhang H, et al. Long non-coding RNAs: emerging and versatile regulators in host-virus interactions. Front Immunol. 2017;8:1663. [
DOI:10.3389/fimmu.2017.01663] [
PMID] [
PMCID]
30. Samson A, Bentham MJ, Scott K, Nuovo G, Bloy A, Appleton E, et al. Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer. Gut. 2018;67(3):562-73. [
DOI:10.1136/gutjnl-2016-312009] [
PMID] [
PMCID]
31. Samudh N, Shrilall C, Arbuthnot P, Bloom K, Ely A. Diversity of dysregulated long non-coding RNAs in HBV-related hepatocellular carcinoma. Front Immunol. 2022;13:834650. [
DOI:10.3389/fimmu.2022.834650] [
PMID] [
PMCID]
32. Sivasudhan E, Blake N, Lu Z, Meng J, Rong R. Hepatitis B viral protein HBx and the molecular mechanisms modulating the hallmarks of hepatocellular carcinoma: a comprehensive review. Cells. 2022;11(4):741. [
DOI:10.3390/cells11040741] [
PMID] [
PMCID]
33. Husein A, Jamal A, Kamal MA, Alqurashi YE, Al-Malki ES, Naiyer MM, et al. Hepatitis B virus-induced hepatocellular carcinoma: HBx-associated epigenetic mechanisms and therapeutic opportunities. Cancer Gene Ther. 2026;33:612-23. [
DOI:10.1038/s41417-026-01051-6] [
PMID]